Acrivon executives receive new stock option awards

Acrivon Therapeutics reported stock option awards to senior executives.

Rhea-AI Filing Summary

Acrivon Therapeutics reported stock option awards to senior executives. The filing shows grants covering 417,210 options and 185,495 options, with exercise rights structured as long-term incentives rather than cash purchases. Twenty-five percent of each grant vests on March 1, 2027, and the remaining options vest in 36 equal monthly installments, conditioned on continued service. Footnotes explain that President and CEO Dr. Peter Blume-Jensen and EVP Dr. Kristina Masson each hold options and disclaim beneficial ownership of their spouse’s securities except for any economic interest.

Insider Trade Summary

Grant/Award: 602,705 shares

Grant/Award 2 txns

Insider Blume-Jensen Peter, Masson Kristina

Role President and CEO | EVP - Business Operations

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	417,210	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	185,495	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 417,210 contracts (Direct); Stock Option (Right to Buy) — 185,495 contracts (Indirect, See Footnote)

Footnotes (3)

1. F1. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.
2. F2. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
3. F3. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions were reported on Acrivon Therapeutics (ACRV) Form 4?

The Form 4 reports two stock option grants to senior executives, covering 417,210 and 185,495 options. These are incentive awards, not open-market purchases, and increase the executives’ potential future equity exposure to Acrivon Therapeutics.

Who received the stock option awards in the ACRV insider filing?

The options are associated with President and CEO Dr. Peter Blume-Jensen and EVP Dr. Kristina Masson. Footnotes clarify that each spouse holds certain securities and disclaims beneficial ownership of the other’s holdings except for any pecuniary interest.

How do the ACRV executive stock options vest?

The options vest over four years. Twenty-five percent of the shares subject to each option vest on March 1, 2027, with the remaining options vesting in 36 substantially equal monthly installments, contingent on continuous service through each vesting date.

What is the exercise price of the Acrivon Therapeutics executive options?

The reported transaction price per option share is $0.00, reflecting a grant of stock options as compensation rather than an open-market purchase. The filing classifies both transactions as awards or other acquisitions of derivative securities.

Do the ACRV executives fully own their spouse’s reported securities?

No. Footnotes state that each executive disclaims beneficial ownership of their spouse’s securities, except to the extent of their pecuniary interest. This clarifies economic exposure while indicating the securities are held in the other spouse’s name.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:15 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.51	03/01/2026		A		417,210		(1)	02/29/2036	Common Stock	417,210	$0	417,210	D(2)
Stock Option (Right to Buy)	$1.51	03/01/2026		A		185,495		(1)	02/29/2036	Common Stock	185,495	$0	185,495	I	See Footnote(3)

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

1. Name and Address of Reporting Person^*

Masson Kristina

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP - Business Operations

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

2. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

3. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

	/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen	03/03/2026
	/s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.